Graham v John Deere 3.15.04 Patent Law. Justice Tom Clark (1899-1977)

Slides:



Advertisements
Similar presentations
Patents Under U.S. Law © 2006 David W. Opderbeck.
Advertisements

Technology Center 1600 Training on Writing Rejections Under 35 U.S.C. § 103.
Priority, Intro to 103 Prof. Merges – Intro to IP
Proteomics Examination Yvonne (Bonnie) Eyler Technology Center 1600 Art Unit 1646 (703)
October 2007KSR Training1 TC 3700 KSR Sample Rejection.
1 35 U.S.C. § 112, first paragraph and the Wands Analysis Remy Yucel, SPE 1636 (571)
1 Rule 132 Declarations and Unexpected Results Richard E. Schafer Administrative Patent Judge Board of Patent Appeals and Interferences.
Patent, Trademark, Copyright, and Enforcement - Law and Policy November 5-8, 2007 United States Patent and Trademark Office Global Intellectual Property.
1 35 USC 112, 1 st paragraph enablement Enablement Practice in TC 1600 Deborah Reynolds, SPE
“REACH-THROUGH CLAIMS”
Determination of Obviousness Practice Under the Genus-Species Guidelines and In re Ochiai; In re Brouwer Sreeni Padmanabhan & James Wilson Supervisory.
Determining Obviousness under 35 USC 103 in view of KSR International Co. v. Teleflex TC3600 Business Methods January 2008.
Nonobviousness Patent Law Prof. Merges –
Nonobviousness Patent Law Prof. Merges –
Vs. Miguel Chan UC Berkeley IEOR 190G March 2009.
Introduction to Nonobviousness Patent Law
Intellectual Property
Intellectual Property Boston College Law School March 5, 2008 Patent – Nonobviousness 2.
KSR vs. Teleflex IEOR 190G Simon Xu
Priority, Intro to 103 Prof. Merges – Intro to IP
Intellectual Property Boston College Law School March 3, 2008 Patent - Nonobviousness.
Patent Overview by Jeff Woller. Why have Patents? Patents make some people rich – but, does that seem like something the government should protect? Do.
Indirect and Foreign Infringement Prof Merges Patent Law –
Patents 101 April 1, 2002 And now, for something new, useful and not obvious.
Intellectual Property Boston College Law School February 16, 2009 Patent – Novelty.
Nonobviousness Patent Law Prof. Merges –
By Paul J. Lee. Disclaimer The opinions and views expressed in these materials are not necessarily those of DexCom and reflect only the personal views.
Examination Issues: Immunology Yvonne (Bonnie) Eyler Quality Assurance Specialist Technology Center 1600 USPTO (571)
Nonobviousness II Intro to IP – Prof Merges
Stem Cells Peter Paras, Jr.. 2 Overview Introduction — Definitions Types of Stem Cells — Origin Examination of Stem Cell Claims — Statutes — Sample Claims.
Utility Requirement in Japan Makoto Ono, Ph.D. Anderson, Mori & Tomotsune Website:
1 ANTICIPATION BY INHERENCY IN PRIOR ART James O. Wilson Supervisory Patent Examiner Technology Center 1600 USPTO (571)
Determining Obviousness Under 35 U.S.C. § 103 After KSR v. Teleflex
Broadening the Scope of the Claims in Gene Therapy Applications Deborah Reynolds Detailee, TCPS
Patenting Wireless Technology: Obviousness Dr. Tal Lavian UC Berkeley Engineering, CET.
©2011 Haynes and Boone, LLP 1 Functional Language in Claims David O’Dell Haynes and Boone LLP
California :: Delaware :: Florida :: New Jersey :: New York :: Pennsylvania :: Virginia :: Washington, DC :: Advice for Drafting.
Routine Optimization Jean Witz, tQAS, TC
Overcoming Prior Art References Non-Enabling Prior Art References Gary Kunz SPE Art Unit 1616.
Obviousness II Class Notes: February 11, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
Josiah Hernandez Patentability Requirements. Useful Having utilitarian or commercial value Novel No one else has done it before If someone has done it.
1 Written Description Analysis and Capon v. Eshhar Jeffrey Siew Supervisory Patent Examiner AU 1645 USPTO (571)
Further Research Considerations April 30, Further Research & Development Considerations April 30, 2015.
102/103 Prior Art and Analogous Arts Patent Law – Professor Merges
New Sections 102 & 103 (b) Conditions for Patentability- (1) IN GENERAL- Section 102 of title 35, United States Code, is amended to read as follows: -`Sec.
Overview Validity of patent hinges on novelty, utility, and non-obviousness Utility generally not an issue Pre-suit investigation focuses on infringement,
1 Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex.
1 Demystifying the Examination of Stem Cell-Related Inventions Remy Yucel, Ph.D. Supervisory Patent Examiner Technology Center 1600 United States Patent.
Examining Claims for Compliance with 35 U.S.C. 112(a): Part II – Enablement Focus on Electrical/Mechanical and Computer/Software-related Claims August.
Vector Claims in Gene Therapy Applications: In vivo vs. In vitro Utilities Deborah Reynolds SPE GAU
Patents IV Nonobviousness
Claims, Anticipation, and Obviousness Kathleen Kahler Fonda Legal Advisor, Office of Patent Legal Administration July 30, 2010.
1 Examination Guidelines Update: Developments in the Obviousness Inquiry After KSR v.Teleflex Biotech/Chem/Pharma Customer Partnership Meeting December.
1 Enablement Issues in Pharmaceutical Claims Joseph K. M c Kane Supervisory Patent Examiner Art Unit Ardin Marschel Supervisory Patent.
Examination Practice in Applications Presenting “Reach-Through Claims” George Elliott Practice Specialist Technology Center 1600
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. TC 1600 Biotech/Chem/Pharma.
Nonobviousness II: More on Nonobviousness The Scope & Content of the Prior Art Law 677 | Patent Law | Spring 2002 Administrative: (1)reminder: Federal.
Obviousness I Class Notes: February 6, 2003 Law 677 | Patent Law | Spring 2003 Professor Wagner.
USPTO Guidelines for Determining Obviousness in View of the Supreme Court Decision in KSR International Co. v. Teleflex Inc. Kathleen Kahler Fonda Legal.
10/18/10 RJM - Sci Ev Seminar - Fall Today’s Agenda Warner-Jenkinson 1. tosinDKTS aka Dockets 2. janeJMNJ aka Jumanji 3. joshJMNJ 4. li(ZL) 2 aka.
BLW 360 – January 27, 2015 Jonathan LA Phillips
Introduction to Intellectual Property Class of Sept
Patents 101 March 28, 2006 And now, for something new, useful and not obvious.
Processes Which Employ Non-Obvious Products
Ram R. Shukla, Ph.D. SPE AU 1632 & 1634 Technology Center
Patents IV Nonobviousness
Global Innovation Management Workout on Writing a Patent
Law 677 | Patent Law | Spring 2003
Stem Cells Peter Paras, Jr.
Examination Issues: Immunology
Presentation transcript:

Graham v John Deere Patent Law

Justice Tom Clark ( )

Clark Trivia "It's not that he's a bad man," rued [Pres. Harry] Truman. "It's just that he's the dumbest sonofabitch I ever met." Clark resigned in 1967 to avoid any question of conflict of interest after President Lyndon B. Johnson appointed Clark's son, Ramsey, to serve as Attorney General.

35 USC Sec 103 § 103. Conditions for patentability; non- obvious subject matter (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Graham points “[T]he 1952 [patent law] revision was not intended to change the general level of patentable invention. Ultimate question of patentability is one of law; lends itself to “several basic factual inquiries”

The Graham Test Scope and content of the prior art Difference between the prior art and the claims at issue Level of ordinary skill in the pertinent art –P. 677

Secondary consdiderations “Might be utilized...” Commercial success Long felt need Failure of other

Hinge Plate Shank Upper Plate Graham v. John Deere Prior Art: ‘811 Patent

Upper Plate Hinge Plate Shank Graham v. John Deere Claimed Invention ‘798 (Modified ‘811 Patent)

Graham v. John Deere Is it obvious to move the hinge plate from position A under the shank to position 1 above the shank? A B C 1 3 2

Federal Circuit and Secondary Factors Elevation of “secondary factors” to a de facto “4 th Graham factor” –See, e.g., Hybritech v Monoclonal Antibodies, Inc., p. 736 –“objective evidence must be considered before a conclusion on obviousness” P. 739

Updating Graham I A showing of obviousness requires [1] a motivation or suggestion to combine or modify prior art references, coupled with [2] a reasonable expectation of success. -- Brown & Williamson Tobacco Corp. v. Philip Morris Inc., 229 F.3d 1120, , (Fed.Cir.2000)

In re O'Farrell, 853 F.2d 894, 903 (Fed.Cir.1988) “Obvious to try” is NOT the appropriate standard While absolute certainty is not necessary to establish a reasonable expectation of success, In re O'Farrell, 853 F.2d 894, , 7 USPQ2d 1673, 1681 (Fed.Cir.1988), there can be little better evidence negating an expectation of success than actual reports of failure. A reasonable jury could conclude from these reports that one of ordinary skill in the art would not have had a reasonable expectation of success...

Updating Graham II For the Johnson article to render the claimed invention obvious, there must have been, at the time the invention was made, a reasonable expectation of success in applying Johnson's teachings. Life Technologies, Inc. v. Clontech Laboratories, 224 F.3d 1320 (Fed Cir 2000)

Updating Graham III Velander v. Garner, 348 F.3d 1359 (Fed. Cir. 2003) How is “reasonable expectation of success” applied?

A method for producing biocompetent fibrinogen comprising: providing a transgenic female non- human mammal carrying in its germline heterologous DNA segments Aα, Bβ, and γ chains of fibrinogen, wherein said segments are expressed in a mammary gland of said mammal and biocompetent fibrinogen encoded by said segments is secreted into milk of said mammal; collecting milk from said mammal; and recovering said biocompetent fibrinogen from said milk.

Garner also argued that one of ordinary skill in the art would have had a reasonable expectation of success in producing biocompetent fibrinogen in the milk of transgenic animals in view of the prior art showing successful production of transgenic animals capable of expressing heterologous proteins in biologically active form. As support for that proposition, Garner cited several authorities [e.g., Greenberg et al., Expression of Biologically Active Heterodimeric Bovine Follicle- stimulating Hormone in Milk of Transgenic Mice, 88 P.N.A.S (1991)]

Garner "absolute predictability" and “obvious to try” are both incorrect standards. In re O'Farrell, 853 F.2d 894, 903 (Fed.Cir.1988). The presence of a reasonable expectation of success is measured from the perspective of a person of ordinary skill in the art at the time the invention was made. Claims here were obvious.